Vol.

No.

March 06, 2026Mar 06, 2026

DOWNLOAD THE PDF

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

Cover Story

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study

Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

By Jacquelyn Cobb and Sara Willa Ernst

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.

Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

By Jacquelyn Cobb and Sara Willa Ernst

Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

By Jacquelyn Cobb and Sara Willa Ernst

Free Obituary

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

By Johns Hopkins Kimmel Cancer Center Communications

Podcast

One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome

Cancer Policy

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, faculty members

House member introduces bill to increase funding for MCD testing of firefighters

In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Bob Gray steps down as ECOG-ACRIN group statistician

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Fred Hutch announces 12 recipients of the annual Harold M. Weintraub Graduate Student Award

UPMC Hillman’s M. Saiful Huq receives recognition for global leadership in cancer care

Five global teams awarded $125M to support cancer science research

Penn Medicine receives $10M to establish the King Center for Lynch Syndrome

Cyberattack on University of Hawaiʻi Cancer Center targeted personal information

Clinical Roundup

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Johns Hopkins investigators create open source database to more easily study cancer data

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

TNBC can become resistant to therapy in more than one way, Baylor study finds

Cell-free DNA offers early warning for bloodstream infections in children with leukemia, St. Jude-led study finds

Combination treatment may dramatically improve survival in brain cancer

Drugs & Targets

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM

FDA grants tentative approval for Lutetium Lu 177 dotatate

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

NCI Trials

NCI Trials for March

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Podcast

One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome

Cancer Policy

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, faculty members

House member introduces bill to increase funding for MCD testing of firefighters

In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Bob Gray steps down as ECOG-ACRIN group statistician

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Fred Hutch announces 12 recipients of the annual Harold M. Weintraub Graduate Student Award

UPMC Hillman’s M. Saiful Huq receives recognition for global leadership in cancer care

Five global teams awarded $125M to support cancer science research

Penn Medicine receives $10M to establish the King Center for Lynch Syndrome

Cyberattack on University of Hawaiʻi Cancer Center targeted personal information

Clinical Roundup

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Johns Hopkins investigators create open source database to more easily study cancer data

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

TNBC can become resistant to therapy in more than one way, Baylor study finds

Cell-free DNA offers early warning for bloodstream infections in children with leukemia, St. Jude-led study finds

Combination treatment may dramatically improve survival in brain cancer

Drugs & Targets

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM

FDA grants tentative approval for Lutetium Lu 177 dotatate

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

NCI Trials

NCI Trials for March

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login